Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Ovarian Research
Published in: Journal of Ovarian Research 1/2012

Open Access 01-12-2012 | Review

Current status and implications of microRNAs in ovarian cancer diagnosis and therapy

Authors: Mohd Saif Zaman, Diane M Maher, Sheema Khan, Meena Jaggi, Subhash C Chauhan

Published in: Journal of Ovarian Research | Issue 1/2012

Login to get access

Abstract

Ovarian cancer is the fifth most common cancer among women and causes more deaths than any other type of female reproductive cancer. Currently, treatment of ovarian cancer is based on the combination of surgery and chemotherapy. While recurrent ovarian cancer responds to additional chemotherapy treatments, the progression-free interval becomes shorter after each cycle, as chemo-resistance increases until the disease becomes incurable. There is, therefore, a strong need for prognostic and predictive markers to help optimize and personalize treatment in order to improve the outcome of ovarian cancer. An increasing number of studies indicate an essential role for microRNAs in ovarian cancer progression and chemo-resistance. MicroRNAs (miRNAs) are small endogenous non-coding RNAs (~22bp) which are frequently dysregulated in cancer. Typically, miRNAs are involved in crucial biological processes, including development, differentiation, apoptosis and proliferation. Two families of miRNAs, miR-200 and let-7, are frequently dysregulated in ovarian cancer and have been associated with poor prognosis. Both have been implicated in the regulation of epithelial-to-mesenchymal transition, a cellular transition associated with tumor aggressiveness, tumor invasion and chemo-resistance. Moreover, miRNAs also have possible implications for improving cancer diagnosis; for example miR-200 family, let-7 family, miR-21 and miR-214 may be useful in diagnostic tests to help detect ovarian cancer at an early stage. Additionally, the use of multiple target O-modified antagomirs (MTG-AMO) to inhibit oncogenic miRNAs and miRNA replacement therapy for tumor suppressor miRNAs are essential tools for miRNA based cancer therapeutics. In this review we describe the current status of the role miRNAs play in ovarian cancer and focus on the possibilities of microRNA-based therapies and the use of microRNAs as diagnostic tools.
Appendix
Available only for authorised users
Literature
1.
Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012,62(1):10–29. 10.3322/caac.20138PubMedCrossRef
2.
Wright JD, Shah M, Mathew L, Burke WM, Culhane J, Goldman N, Schiff PB, Herzog TJ: Fertility preservation in young women with epithelial ovarian cancer. Cancer 2009,115(18):4118–4126. 10.1002/cncr.24461PubMedCrossRef
3.
Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P: Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol 2007,14(5):195–208. 10.3747/co.2007.148PubMedCentralPubMedCrossRef
4.
Takano M, Kikuchi Y, Yaegashi N, Kuzuya K, Ueki M, Tsuda H, Suzuki M, Kigawa J, Takeuchi S, Moriya T, et al.: Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 2006,94(10):1369–1374. 10.1038/sj.bjc.6603116PubMedCentralPubMedCrossRef
5.
du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, et al.: A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003,95(17):1320–1329. 10.1093/jnci/djg036PubMedCrossRef
6.
Shih Ie M, Kurman RJ: Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004,164(5):1511–1518. 10.1016/S0002-9440(10)63708-XPubMedCrossRef
7.
Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, et al.: Ovarian Cancer, Version 3.2012. J Natl Compr Canc Netw 2012,10(11):1339–1349.PubMed
8.
Vergote I, du Bois A, Amant F, Heitz F, Leunen K, Harter P: Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree. Gynecol Oncol 2012. Sep 21 (Epub ahead of print).
9.
Gonzalez-Martin A, Chiva L: Emerging Concerns When Evidence-Based Medicine Is Translated into Real Life: The Case of Neoadjuvant Chemotherapy in Ovarian Cancer. Curr Oncol Rep 2012. Oct 9 (epub ahead of print).
10.
11.
Rabik CA, Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007,33(1):9–23. 10.1016/j.ctrv.2006.09.006PubMedCentralPubMedCrossRef
12.
Fraser M, Bai T, Tsang BK: Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Int J Cancer 2008,122(3):534–546. 10.1002/ijc.23086PubMedCrossRef
13.
Behbakht K, Qamar L, Aldridge CS, Coletta RD, Davidson SA, Thorburn A, Ford HL: Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival. Cancer Res 2007,67(7):3036–3042. 10.1158/0008-5472.CAN-06-3755PubMedCrossRef
14.
Duan Z, Foster R, Bell DA, Mahoney J, Wolak K, Vaidya A, Hampel C, Lee H, Seiden MV: Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res 2006,12(17):5055–5063. 10.1158/1078-0432.CCR-06-0861PubMedCrossRef
15.
Gan Y, Wientjes MG, Au JL: Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors. Pharm Res 2006,23(6):1324–1331. 10.1007/s11095-006-0136-6PubMedCrossRef
16.
Ferlini C, Raspaglio G, Cicchillitti L, Mozzetti S, Prislei S, Bartollino S, Scambia G: Looking at drug resistance mechanisms for microtubule interacting drugs: does TUBB3 work? Curr Cancer Drug Targets 2007,7(8):704–712. 10.2174/156800907783220453PubMedCrossRef
17.
Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004,116(2):281–297. 10.1016/S0092-8674(04)00045-5PubMedCrossRef
18.
Bartels CL, Tsongalis GJ: MicroRNAs: novel biomarkers for human cancer. Clin Chem 2009,55(4):623–631. 10.1373/clinchem.2008.112805PubMedCrossRef
19.
Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C: Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 2008,111(3):478–486. 10.1016/j.ygyno.2008.08.017PubMedCrossRef
20.
Marchini S, Fruscio R, Clivio L, Beltrame L, Porcu L, Nerini IF, Cavalieri D, Chiorino G, Cattoretti G, Mangioni C, et al.: Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Eur J Cancer 2012. Aug 13, (Epub ahead of print).
21.
Ye G, Fu G, Cui S, Zhao S, Bernaudo S, Bai Y, Ding Y, Zhang Y, Yang BB, Peng C: MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance. J Cell Sci 2011,124(Pt 3):359–368.PubMedCrossRef
22.
Lee RC, Feinbaum RL, Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993,75(5):843–854. 10.1016/0092-8674(93)90529-YPubMedCrossRef
23.
Wheeler BM, Heimberg AM, Moy VN, Sperling EA, Holstein TW, Heber S, Peterson KJ: The deep evolution of metazoan microRNAs. Evol Dev 2009,11(1):50–68. 10.1111/j.1525-142X.2008.00302.xPubMedCrossRef
24.
25.
Cai X, Hagedorn CH, Cullen BR: Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA 2004,10(12):1957–1966. 10.1261/rna.7135204PubMedCentralPubMedCrossRef
26.
27.
Pratt AJ, MacRae IJ: The RNA-induced silencing complex: a versatile gene-silencing machine. J Biol Chem 2009,284(27):17897–17901. 10.1074/jbc.R900012200PubMedCentralPubMedCrossRef
28.
Fabian MR, Mathonnet G, Sundermeier T, Mathys H, Zipprich JT, Svitkin YV, Rivas F, Jinek M, Wohlschlegel J, Doudna JA, et al.: Mammalian miRNA RISC recruits CAF1 and PABP to affect PABP-dependent deadenylation. Mol Cell 2009,35(6):868–880. 10.1016/j.molcel.2009.08.004PubMedCentralPubMedCrossRef
29.
Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP: MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 2007,27(1):91–105. 10.1016/j.molcel.2007.06.017PubMedCentralPubMedCrossRef
30.
Gu S, Jin L, Zhang F, Sarnow P, Kay MA: Biological basis for restriction of microRNA targets to the 3' untranslated region in mammalian mRNAs. Nat Struct Mol Biol 2009,16(2):144–150. 10.1038/nsmb.1552PubMedCentralPubMedCrossRef
31.
Vasudevan S, Tong Y, Steitz JA: Cell-cycle control of microRNA-mediated translation regulation. Cell Cycle 2008,7(11):1545–1549. 10.4161/cc.7.11.6018PubMedCentralPubMedCrossRef
32.
Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB: Prediction of mammalian microRNA targets. Cell 2003,115(7):787–798. 10.1016/S0092-8674(03)01018-3PubMedCrossRef
33.
Flynt AS, Lai EC: Biological principles of microRNA-mediated regulation: shared themes amid diversity. Nat Rev Genet 2008,9(11):831–842. 10.1038/nrg2455PubMedCentralPubMedCrossRef
34.
Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al.: Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002,99(24):15524–15529. 10.1073/pnas.242606799PubMedCentralPubMedCrossRef
35.
36.
Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, et al.: A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005,353(17):1793–1801. 10.1056/NEJMoa050995PubMedCrossRef
37.
Calin GA, Croce CM: Chromosomal rearrangements and microRNAs: a new cancer link with clinical implications. J Clin Invest 2007,117(8):2059–2066. 10.1172/JCI32577PubMedCentralPubMedCrossRef
38.
Tagawa H, Seto M: A microRNA cluster as a target of genomic amplification in malignant lymphoma. Leukemia 2005,19(11):2013–2016. 10.1038/sj.leu.2403942PubMedCrossRef
39.
Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, et al.: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004,101(9):2999–3004. 10.1073/pnas.0307323101PubMedCentralPubMedCrossRef
40.
Giannakakis A, Sandaltzopoulos R, Greshock J, Liang S, Huang J, Hasegawa K, Li C, O'Brien-Jenkins A, Katsaros D, Weber BL, et al.: miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther 2008, 7: 255–264. 10.4161/cbt.7.2.5297PubMedCentralPubMedCrossRef
41.
Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, Jones PA: Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006,9(6):435–443. 10.1016/j.ccr.2006.04.020PubMedCrossRef
42.
Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et al.: MicroRNA signatures in human ovarian cancer. Cancer Res 2007,67(18):8699–8707. 10.1158/0008-5472.CAN-07-1936PubMedCrossRef
43.
Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T: Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 2007,39(5):673–677. 10.1038/ng2003PubMedCrossRef
44.
He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, et al.: A microRNA component of the p53 tumour suppressor network. Nature 2007,447(7148):1130–1134. 10.1038/nature05939PubMedPubMedCentralCrossRef
45.
Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, Liu CG, Giannakakis A, Alexiou P, Hasegawa K, et al.: Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A 2008,105(19):7004–7009. 10.1073/pnas.0801615105PubMedCentralPubMedCrossRef
46.
Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A, Liang S, Naylor TL, Barchetti A, Ward MR, et al.: microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A 2006,103(24):9136–9141. 10.1073/pnas.0508889103PubMedCentralPubMedCrossRef
47.
Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, Kim JW, Kim S: MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 2008,14(9):2690–2695. 10.1158/1078-0432.CCR-07-1731PubMedCrossRef
48.
Dahiya N, Sherman-Baust CA, Wang TL, Davidson B, Shih Ie M, Zhang Y, Becker KG, Morin PJ, Wood W: MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One 2008,3(6):e2436. 10.1371/journal.pone.0002436PubMedCentralPubMedCrossRef
49.
Wyman SK, Parkin RK, Mitchell PS, Fritz BR, O'Briant K, Godwin AK, Urban N, Drescher CW, Knudsen BS, Tewari M: Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One 2009,4(4):e5311. 10.1371/journal.pone.0005311PubMedCentralPubMedCrossRef
50.
Lee CH, Subramanian S, Beck AH, Espinosa I, Senz J, Zhu SX, Huntsman D, van de Rijn M, Gilks CB: MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary. PLoS One 2009,4(10):e7314. 10.1371/journal.pone.0007314PubMedCentralPubMedCrossRef
51.
Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, et al.: MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008,68(2):425–433. 10.1158/0008-5472.CAN-07-2488PubMedCrossRef
52.
Korpal M, Lee ES, Hu G, Kang Y: The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008,283(22):14910–14914. 10.1074/jbc.C800074200PubMedCentralPubMedCrossRef
53.
Huber MA, Kraut N, Beug H: Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005,17(5):548–558. 10.1016/j.ceb.2005.08.001PubMedCrossRef
54.
Park SM, Gaur AB, Lengyel E, Peter ME: The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008,22(7):894–907. 10.1101/gad.1640608PubMedCentralPubMedCrossRef
55.
Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008,10(5):593–601. 10.1038/ncb1722PubMedCrossRef
56.
Gregory PA, Bracken CP, Bert AG, Goodall GJ: MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle 2008,7(20):3112–3118. 10.4161/cc.7.20.6851PubMedCrossRef
57.
Kong D, Li Y, Wang Z, Banerjee S, Ahmad A, Kim HR, Sarkar FH: miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells 2009,27(8):1712–1721. 10.1002/stem.101PubMedCentralPubMedCrossRef
58.
Imai T, Horiuchi A, Shiozawa T, Osada R, Kikuchi N, Ohira S, Oka K, Konishi I: Elevated expression of E-cadherin and alpha-, beta-, and gamma-catenins in metastatic lesions compared with primary epithelial ovarian carcinomas. Hum Pathol 2004,35(12):1469–1476. 10.1016/j.humpath.2004.09.014PubMedCrossRef
59.
Leskela S, Leandro-Garcia LJ, Mendiola M, Barriuso J, Inglada-Perez L, Munoz I, Martinez-Delgado B, Redondo A, de Santiago J, Robledo M, et al.: The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer 2011,18(1):85–95.PubMedCrossRef
60.
Rosell R, Scagliotti G, Danenberg KD, Lord RV, Bepler G, Novello S, Cooc J, Crino L, Sanchez JJ, Taron M, et al.: Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 2003,22(23):3548–3553. 10.1038/sj.onc.1206419PubMedCrossRef
61.
Seve P, Mackey J, Isaac S, Tredan O, Souquet PJ, Perol M, Lai R, Voloch A, Dumontet C: Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005,4(12):2001–2007. 10.1158/1535-7163.MCT-05-0244PubMedCrossRef
62.
Seve P, Dumontet C: Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol 2008,9(2):168–175. 10.1016/S1470-2045(08)70029-9PubMedCrossRef
63.
Koh Y, Kim TM, Jeon YK, Kwon TK, Hah JH, Lee SH, Kim DW, Wu HG, Rhee CS, Sung MW, et al.: Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. Ann Oncol 2009,20(8):1414–1419. 10.1093/annonc/mdp002PubMedCrossRef
64.
Ferrandina G, Zannoni GF, Martinelli E, Paglia A, Gallotta V, Mozzetti S, Scambia G, Ferlini C: Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 2006,12(9):2774–2779. 10.1158/1078-0432.CCR-05-2715PubMedCrossRef
65.
Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M, Horwitz SB: Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 1997,100(5):1282–1293. 10.1172/JCI119642PubMedCentralPubMedCrossRef
66.
Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, Prislei S, Gallo D, Martinelli E, Ranelletti FO, Ferrandina G, et al.: Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 2005,11(1):298–305.PubMed
67.
Umezu T, Shibata K, Kajiyama H, Terauchi M, Ino K, Nawa A, Kikkawa F: Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin. Int J Gynecol Pathol 2008,27(2):207–212.PubMed
68.
Roush S, Slack FJ: The let-7 family of microRNAs. Trends Cell Biol 2008,18(10):505–516. 10.1016/j.tcb.2008.07.007PubMedCrossRef
69.
Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI, Maller B, Hayward DC, Ball EE, Degnan B, Muller P, et al.: Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 2000,408(6808):86–89. 10.1038/35040556PubMedCrossRef
70.
Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, et al.: Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004,64(11):3753–3756. 10.1158/0008-5472.CAN-04-0637PubMedCrossRef
71.
Yang N, Kaur S, Volinia S, Greshock J, Lassus H, Hasegawa K, Liang S, Leminen A, Deng S, Smith L, et al.: MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 2008,68(24):10307–10314. 10.1158/0008-5472.CAN-08-1954PubMedCentralPubMedCrossRef
72.
Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ: RAS is regulated by the let-7 microRNA family. Cell 2005,120(5):635–647. 10.1016/j.cell.2005.01.014PubMedCrossRef
73.
Bussing I, Slack FJ, Grosshans H: let-7 microRNAs in development, stem cells and cancer. Trends Mol Med 2008,14(9):400–409. 10.1016/j.molmed.2008.07.001PubMedCrossRef
74.
Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, Wilson M, Wang X, Shelton J, Shingara J, et al.: The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 2007,67(16):7713–7722. 10.1158/0008-5472.CAN-07-1083PubMedCrossRef
75.
Schultz J, Lorenz P, Gross G, Ibrahim S, Kunz M: MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res 2008,18(5):549–557. 10.1038/cr.2008.45PubMedCrossRef
76.
Wang Y, Hu X, Greshock J, Shen L, Yang X, Shao Z, Liang S, Tanyi JL, Sood AK, Zhang L: Genomic DNA Copy-Number Alterations of the let-7 Family in Human Cancers. PLoS One 2012,7(9):e44399. 10.1371/journal.pone.0044399PubMedCentralPubMedCrossRef
77.
Chen GQ, Zhao ZW, Zhou HY, Liu YJ, Yang HJ: Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin. Med Oncol 2010,27(2):406–415. 10.1007/s12032-009-9225-9PubMedCrossRef
78.
Blower PE, Chung JH, Verducci JS, Lin S, Park JK, Dai Z, Liu CG, Schmittgen TD, Reinhold WC, Croce CM, et al.: MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther 2008,7(1):1–9. 10.1158/1535-7163.MCT-07-0573PubMedCrossRef
79.
Weidhaas JB, Babar I, Nallur SM, Trang P, Roush S, Boehm M, Gillespie E, Slack FJ: MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res 2007,67(23):11111–11116. 10.1158/0008-5472.CAN-07-2858PubMedCrossRef
80.
Boyerinas B, Park SM, Murmann AE, Gwin K, Montag AG, Zillhardt M, Hua YJ, Lengyel E, Peter ME: Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Int J Cancer 2012,130(8):1787–1797. 10.1002/ijc.26190PubMedCentralPubMedCrossRef
81.
Lu L, Schwartz P, Scarampi L, Rutherford T, Canuto EM, Yu H, Katsaros D: MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management. Gynecol Oncol 2011,122(2):366–371. 10.1016/j.ygyno.2011.04.033PubMedCrossRef
82.
Corney DC, Hwang CI, Matoso A, Vogt M, Flesken-Nikitin A, Godwin AK, Kamat AA, Sood AK, Ellenson LH, Hermeking H, et al.: Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res 2010,16(4):1119–1128. 10.1158/1078-0432.CCR-09-2642PubMedCentralPubMedCrossRef
83.
Nagaraja AK, Creighton CJ, Yu Z, Zhu H, Gunaratne PH, Reid JG, Olokpa E, Itamochi H, Ueno NT, Hawkins SM, et al.: A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol 2010,24(2):447–463. 10.1210/me.2009-0295PubMedCentralPubMedCrossRef
84.
Peng DX, Luo M, Qiu LW, He YL, Wang XF: Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer. Oncol Rep 2012,27(4):1238–1244.PubMedCentralPubMed
85.
Mabuchi S, Kawase C, Altomare DA, Morishige K, Sawada K, Hayashi M, Tsujimoto M, Yamoto M, Klein-Szanto AJ, Schilder RJ, et al.: mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res 2009,15(17):5404–5413. 10.1158/1078-0432.CCR-09-0365PubMedCentralPubMedCrossRef
86.
Creighton CJ, Fountain MD, Yu Z, Nagaraja AK, Zhu H, Khan M, Olokpa E, Zariff A, Gunaratne PH, Matzuk MM, et al.: Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers. Cancer Res 2010,70(5):1906–1915. 10.1158/0008-5472.CAN-09-3875PubMedCentralPubMedCrossRef
87.
Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, et al.: Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol 2010,11(2):136–146. 10.1016/S1470-2045(09)70343-2PubMedCentralPubMedCrossRef
88.
Penna E, Orso F, Cimino D, Tenaglia E, Lembo A, Quaglino E, Poliseno L, Haimovic A, Osella-Abate S, De Pitta C, et al.: microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO J 2011,30(10):1990–2007. 10.1038/emboj.2011.102PubMedCentralPubMedCrossRef
89.
Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al.: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006,103(7):2257–2261. 10.1073/pnas.0510565103PubMedCentralPubMedCrossRef
90.
Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, Barbosa-Morais NL, Teschendorff AE, Green AR, Ellis IO, et al.: MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 2007,8(10):R214. 10.1186/gb-2007-8-10-r214PubMedCentralPubMedCrossRef
91.
Qiang R, Wang F, Shi LY, Liu M, Chen S, Wan HY, Li YX, Li X, Gao SY, Sun BC, et al.: Plexin-B1 is a target of miR-214 in cervical cancer and promotes the growth and invasion of HeLa cells. Int J Biochem Cell Biol 2011,43(4):632–641. 10.1016/j.biocel.2011.01.002PubMedCrossRef
92.
93.
Yin G, Chen R, Alvero AB, Fu HH, Holmberg J, Glackin C, Rutherford T, Mor G: TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214. Oncogene 2010,29(24):3545–3553. 10.1038/onc.2010.111PubMedCentralPubMedCrossRef
94.
Lee MS, Lowe GN, Strong DD, Wergedal JE, Glackin CA: TWIST, a basic helix-loop-helix transcription factor, can regulate the human osteogenic lineage. J Cell Biochem 1999,75(4):566–577. 10.1002/(SICI)1097-4644(19991215)75:4<566::AID-JCB3>3.0.CO;2-0PubMedCrossRef
95.
Lee MS, Lowe G, Flanagan S, Kuchler K, Glackin CA: Human Dermo-1 has attributes similar to twist in early bone development. Bone 2000,27(5):591–602. 10.1016/S8756-3282(00)00380-XPubMedCrossRef
96.
Bialek P, Kern B, Yang X, Schrock M, Sosic D, Hong N, Wu H, Yu K, Ornitz DM, Olson EN, et al.: A twist code determines the onset of osteoblast differentiation. Dev Cell 2004,6(3):423–435. 10.1016/S1534-5807(04)00058-9PubMedCrossRef
97.
Ota MS, Loebel DA, O'Rourke MP, Wong N, Tsoi B, Tam PP: Twist is required for patterning the cranial nerves and maintaining the viability of mesodermal cells. Dev Dyn 2004,230(2):216–228. 10.1002/dvdy.20047PubMedCrossRef
98.
Li Z, Lu J, Sun M, Mi S, Zhang H, Luo RT, Chen P, Wang Y, Yan M, Qian Z, et al.: Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A 2008,105(40):15535–15540. 10.1073/pnas.0808266105PubMedCentralPubMedCrossRef
99.
Xu G, Zhong Y, Munir S, Yang BB, Tsang BK, Peng C: Nodal induces apoptosis and inhibits proliferation in human epithelial ovarian cancer cells via activin receptor-like kinase 7. J Clin Endocrinol Metab 2004,89(11):5523–5534. 10.1210/jc.2004-0893PubMedCrossRef
100.
Li Y, Tan W, Neo TW, Aung MO, Wasser S, Lim SG, Tan TM: Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma. Cancer Sci 2009,100(7):1234–1242. 10.1111/j.1349-7006.2009.01164.xPubMedCrossRef
101.
Fang L, Deng Z, Shatseva T, Yang J, Peng C, Du WW, Yee AJ, Ang LC, He C, Shan SW, et al.: MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-beta8. Oncogene 2011,30(7):806–821. 10.1038/onc.2010.465PubMedCrossRef
102.
Fu X, Tian J, Zhang L, Chen Y, Hao Q: Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett 2012,586(9):1279–1286. 10.1016/j.febslet.2012.03.006PubMedCrossRef
103.
Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK, Testa JR: AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004,23(34):5853–5857. 10.1038/sj.onc.1207721PubMedCrossRef
104.
Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY: miR-21-mediated tumor growth. Oncogene 2007,26(19):2799–2803. 10.1038/sj.onc.1210083PubMedCrossRef
105.
Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, Nenutil R, Vyzula R: Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 2007,72(5–6):397–402.PubMedCrossRef
106.
Lou Y, Yang X, Wang F, Cui Z, Huang Y: MicroRNA-21 promotes the cell proliferation, invasion and migration abilities in ovarian epithelial carcinomas through inhibiting the expression of PTEN protein. Int J Mol Med 2010,26(6):819–827.PubMedCrossRef
107.
Polytarchou C, Iliopoulos D, Hatziapostolou M, Kottakis F, Maroulakou I, Struhl K, Tsichlis PN: Akt2 regulates all Akt isoforms and promotes resistance to hypoxia through induction of miR-21 upon oxygen deprivation. Cancer Res 2011,71(13):4720–4731. 10.1158/0008-5472.CAN-11-0365PubMedCentralPubMedCrossRef
108.
Li J, Liang S, Yu H, Zhang J, Ma D, Lu X: An inhibitory effect of miR-22 on cell migration and invasion in ovarian cancer. Gynecol Oncol 2010,119(3):543–548. 10.1016/j.ygyno.2010.08.034PubMedCrossRef
109.
Kim TH, Kim YK, Kwon Y, Heo JH, Kang H, Kim G, An HJ: Deregulation of miR-519a, 153, and 485–5p and its clinicopathological relevance in ovarian epithelial tumours. Histopathology 2010,57(5):734–743. 10.1111/j.1365-2559.2010.03686.xPubMedCrossRef
110.
Lu L, Katsaros D, de la Longrais IA, Sochirca O, Yu H: Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res 2007,67(21):10117–10122. 10.1158/0008-5472.CAN-07-2544PubMedCrossRef
111.
Hu X, Macdonald DM, Huettner PC, Feng Z, El Naqa IM, Schwarz JK, Mutch DG, Grigsby PW, Powell SN, Wang X: A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol 2009,114(3):457–464. 10.1016/j.ygyno.2009.05.022PubMedCrossRef
112.
Taylor DD, Gercel-Taylor C: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008,110(1):13–21. 10.1016/j.ygyno.2008.04.033PubMedCrossRef
113.
Shell S, Park SM, Radjabi AR, Schickel R, Kistner EO, Jewell DA, Feig C, Lengyel E, Peter ME: Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci U S A 2007,104(27):11400–11405. 10.1073/pnas.0704372104PubMedCentralPubMedCrossRef
114.
Garzon R, Marcucci G, Croce CM: Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010,9(10):775–789. 10.1038/nrd3179PubMedCentralPubMedCrossRef
115.
Lu Y, Xiao J, Lin H, Bai Y, Luo X, Wang Z, Yang B: A single anti-microRNA antisense oligodeoxyribonucleotide (AMO) targeting multiple microRNAs offers an improved approach for microRNA interference. Nucleic Acids Res 2009,37(3):e24. 10.1093/nar/gkn1053PubMedCentralPubMedCrossRef
116.
Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, Omotola M, Homer R, Brown D, Bader AG, Weidhaas JB, et al.: Regression of murine lung tumors by the let-7 microRNA. Oncogene 2010,29(11):1580–1587. 10.1038/onc.2009.445PubMedCentralPubMedCrossRef
117.
Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D, Weidhaas JB, Bader AG, Slack FJ: Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 2011,19(6):1116–1122. 10.1038/mt.2011.48PubMedCentralPubMedCrossRef
118.
Pramanik D, Campbell NR, Karikari C, Chivukula R, Kent OA, Mendell JT, Maitra A: Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther 2011,10(8):1470–1480. 10.1158/1535-7163.MCT-11-0152PubMedCentralPubMedCrossRef
119.
Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K: Modulation of microRNA processing by p53. Nature 2009,460(7254):529–533. 10.1038/nature08199PubMedCrossRef
120.
Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, et al.: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011,17(2):211–215. 10.1038/nm.2284PubMedCentralPubMedCrossRef
121.
Melo S, Villanueva A, Moutinho C, Davalos V, Spizzo R, Ivan C, Rossi S, Setien F, Casanovas O, Simo-Riudalbas L, et al.: Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc Natl Acad Sci U S A 2011,108(11):4394–4399. 10.1073/pnas.1014720108PubMedCentralPubMedCrossRef
122.
Shan G, Li Y, Zhang J, Li W, Szulwach KE, Duan R, Faghihi MA, Khalil AM, Lu L, Paroo Z, et al.: A small molecule enhances RNA interference and promotes microRNA processing. Nat Biotechnol 2008,26(8):933–940. 10.1038/nbt.1481PubMedCentralPubMedCrossRef
123.
Jeon HM, Sohn YW, Oh SY, Kim SH, Beck S, Kim S, Kim H: ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9*-mediated suppression of SOX2. Cancer Res 2011,71(9):3410–3421. 10.1158/0008-5472.CAN-10-3340PubMedCrossRef
124.
Cittelly DM, Das PM, Salvo VA, Fonseca JP, Burow ME, Jones FE: Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis 2010,31(12):2049–2057. 10.1093/carcin/bgq192PubMedCentralPubMedCrossRef
125.
Hwang JH, Voortman J, Giovannetti E, Steinberg SM, Leon LG, Kim YT, Funel N, Park JK, Kim MA, Kang GH, et al.: Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One 2010,5(5):e10630. 10.1371/journal.pone.0010630PubMedCentralPubMedCrossRef
Metadata
Title
Current status and implications of microRNAs in ovarian cancer diagnosis and therapy
Authors
Mohd Saif Zaman
Diane M Maher
Sheema Khan
Meena Jaggi
Subhash C Chauhan
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Ovarian Research / Issue 1/2012
Electronic ISSN: 1757-2215
DOI
https://doi.org/10.1186/1757-2215-5-44

Other articles of this Issue 1/2012

Journal of Ovarian Research 1/2012 Go to the issue

Research

High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer

Review

Involvement of autophagy in ovarian cancer: a working hypothesis

Brief communication

Expression of the global regulator SATB1 is an independent factor of poor prognosis in high grade epithelial ovarian cancer

Research

Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis

Research

Adrenocortical steroid response to ACTH in different phenotypes of non-obese polycystic ovary syndrome

Research

Immunoreactivities of androgen receptor, estrogen receptors, p450arom, p450c17 proteins in wild ground squirrels ovaries during the nonbreeding and breeding seasons